Homburger with Windward Bio on licensing deal with Qyuns
Homburger advised Windward Bio Group — a Swiss-based biotechnology specialist in advanced immunological diseases — in connection with a licensing agreement between the company’s affiliate, LE2025 Therapeutics, and Qyuns Therapeutics Co. for the development and commercialization of WIN027, a long-acting bispecific antibody targeting TSLP and IL-13.
Pursuant to the deal, Windward Bio gains exclusive rights to develop, manufacture, and commercialise WIN027 outside of China, for a total of up to USD 700 million, consisting of upfront equity consideration, development and commercial milestones, and tiered royalties.
The Homburger team
The Homburger team working on the matter includes Andreas Müller (pictured), Margrit Marti, Timo Hasler and Lucas Forrer (all healthcare, life sciences, as well as corporate/M&A), Stefan Oesterhelt and Juliette Buob (both tax)
